Bio-Rad Laboratories traded at $356.26 this Friday August 14th, decreasing $4.93 or 1.36 percent since the previous trading session. Looking back, over the last four weeks, Bio-Rad Laboratories lost 20.47 percent. Over the last 12 months, its price rose by 24.71 percent. Looking ahead, we forecast Bio-Rad Laboratories to be priced at 348.60 by the end of this quarter and at 326.60 in one year, according to Trading Economics global macro models projections and analysts expectations.
Bio-Rad Laboratories, Inc. manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate chemical and biological materials and to identify, analyze and purify their components. The Company operates through two segments: Life Science and Clinical Diagnostics. Life Science segment markets and develops, manufactures and markets approximately 6,000 reagents, apparatus and laboratory instruments. Its products are used in research techniques, biopharmaceutical production processes and food testing regimes. Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market.